NOT-CA-24-093: Notice of Change to Expiration Date for NCI Career Development Award Notices of Funding Opportunity (NOFOs): PAR-21-299, PAR-21-300, PAR-21-301, and PAR-21-302

Notice of Change to Expiration Date for NCI Career Development Award Notices of Funding Opportunity (NOFOs): PAR-21-299, PAR-21-300, PAR-21-301, and PAR-21-302

Notice Number:

NOT-CA-24-093

Key Dates

Release Date:

August 15, 2024

Related Announcements

September 10, 2021 - NCI Transition Career Development Award to Promote Diversity (K22 Clinical Trial Required). See PAR-21-302
September 10, 2021 - NCI Transition Career Development Award to Promote Diversity (K22 Independent Clinical Trial Not Allowed). See PAR-21-301
September 10, 2021 - NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 - Independent Clinical. See PAR-21-300
September 10, 2021 - NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Clinical Trial Required). See PAR-21-299

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this notice is to inform potential applicants of the extension of the expiration dates for the following four notices of funding opportunities (NOFOs) - the expiration dates for these four NOFOs have been extended from September 8, 2024, to January 8, 2025:

PAR-21-299: NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Clinical Trial Required)
PAR-21-300: NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 - Independent Clinical Trial Not Allowed)
PAR-21-301: NCI Transition Career Development Award to Promote Diversity (K22 Independent Clinical Trial Not Allowed)
PAR-21-302: NCI Transition Career Development Award to Promote Diversity (K22 Clinical Trial Required)

In Part 1. Overview Information, Key Dates of PAR-21-299, PAR-21-300, PAR-21-301, and PAR-21-302:

Currently reads:

Expiration Date

September 8, 2024

Changed to read (in italics):

Expiration Date

January 8, 2025

All other aspects of PAR-21-299, PAR-21-300, PAR-21-301, and PAR-21-302 remain unchanged.

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)
Shahrooz Vahedi., Ph.D
National Cancer Institute (NCI)
Telephone: 240-276-7754
Email: shahrooz.vahedi@nih.gov

Peer Review Contact(s)
Referral Officer
National Cancer Institute (NCI)
Telephone: 240-276-6390
Email: ncirefof@dea.nci.nih.gov

Financial/Grants Management Contact(s)
Sean Hine
National Cancer Institute (NCI)
Telephone: 240-276-6291
Email: hines@mail.nih.gov